/PRNewswire/ -- Haymaker Acquisition Corp. 4 (NYSE: HYAC U) (the "Company") announced today that, commencing September 15, 2023, holders of the units sold in...
biote Corp., (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today announced that it has completed...
NEW YORK, May 24, 2022 (GLOBE NEWSWIRE) -- Haymaker Acquisition Corp. III (Nasdaq: HYAC) (“Haymaker” or the “Company”), a publicly traded special purpose...
Biote , a high growth, differentiated medical practice-building business within the hormone optimization space, today announced financial results for the first quarter of 2022. Similar to a franchise model,...
Record net sales of $139.4 million for the full year, a 20% increase year-over-year.Record net sales of $37.5 million in the fourth quarter, a 22% increase...
BioTE Holdings, LLC, (Biote), a high-growth, differentiated medical practice-building business within the hormone optimization space (“Biote”), and Haymaker Acquisition Corp. III (Nasdaq: HYAC) (“Haymaker”),...
NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Haymaker Acquisition Corp. III (NASDAQ: HYACU) (the “Company”) today announced that, commencing April 22, 2021, holders of the units sold in the Company’s...
NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Haymaker Acquisition Corp. III (the "Company") (NASDAQ: HYACU) today announced that it closed its initial public offering of 30,000,000 units. The offering...
NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) -- Haymaker Acquisition Corp. III (the "Company") today announced the pricing of its initial public offering of 30,000,000 units at a price of $10.00 per unit....